⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights

Company

CRO Partners
Contact Us
Privacy Policy

© 2025 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Pamrevlumab (pamrevlumab) | Accelerate Your Fibrosis Research

Home/Drugs/Pamrevlumab

Pamrevlumab

pamrevlumab

Phase 3

Sponsor: FibroGen

Indication: IPF / Pancreatic Cancer

Mechanism of Action

Connective Tissue Growth Factor (CTGF) inhibitor

Target: CTGF

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT00102297

Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus

Phase:PHASE1Org:FibroGen

COMPLETED

Relevant Publications (PubMed)

Breaking new ground in heart failure management: novel therapies and future frontiers.

Khalid A, Rodriguez P, Tasouli-Drakou V et al.

Front Cardiovasc Med2025

New Challenging Systemic Therapies for Juvenile Scleroderma: A Comprehensive Review.

Sassetti C, Borrelli C, Mazuy M et al.

Pharmaceuticals (Basel)2025 Apr 28

Minimum clinically important difference in Quantitative Lung Fibrosis score associated with all-cause mortality in idiopathic pulmonary fibrosis: subanalysis from two phase II trials of pamrevlumab.

Kim GH, Zhang X, Brown MS et al.

BMJ Open2025 May 12

"Regression to the truth": lessons learned from negative IPF trials.

Validated Models

This drug has been validated in the following preclinical models:

NCT00754143

Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy

Phase:PHASE1Org:FibroGen

COMPLETEDNCT05262309

An Open-label, Randomized, Parallel-arm Study Investigating the Efficacy and Safety of Intravenous Administration of Pamrevlumab Versus Standard of Care in Patients With COVID-19

Phase:PHASE2, PHASE3Org:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

TERMINATEDNCT02606136

Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

Phase:PHASE2Org:FibroGen

WITHDRAWNNCT02851381

Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer

Phase:NAOrg:Jonsson Comprehensive Cancer Center

View all trials on ClinicalTrials.gov

Trachalaki A, Lindahl AL, Petrarulo S et al.

Breathe (Sheff)2025 Apr

The latest developments in synthetic approaches to Duchenne muscular dystrophy.

Johnson LM, Pulskamp TG, Berlau DJ

Expert Rev Neurother2025 Feb 4

View more on PubMed